Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

2096 - A classifier of 53BP1, immune score and texture analysis of MRI images can predict pathological response to chemoradiotherapy in locally advanced rectal cancer

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Staging and Imaging;  Tumour Immunology

Tumour Site

Colon and Rectal Cancer

Presenters

Hong Ma

Citation

Annals of Oncology (2018) 29 (suppl_8): viii150-viii204. 10.1093/annonc/mdy281

Authors

H. Ma, J. Yao, A. Huang, Y. Xiao, L. Fan

Author affiliations

  • Cancer Center,, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology,, 430022 - Wuhan/CN

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2096

Background

Preoperative chemoradiotherapy is the standard care for advanced rectal cancer. Yet, predicting the response remains a challenge. Our previous studies found that 53BP1 protein deletion leaded to chemoradiotherapy resistance.53BP1 deficiency played pivotal role in inducing lymphocyte mature. As the development of functional imaging, texture analysis can predict response to chemoradiotherapy. Our study aims to explore the relationship among 53BP1 protein, immune score, texture analysis and radiation sensitivity, then set a new classifier to predict response in advanced rectal cancer.

Methods

We enrolled 57 advanced rectal cancer patients who received neoadjuvant chemoradiotherapy in Wuhan Union hospital from January 2015 to January 2018. The expression of 53BP1, CD3, CD8, CD45RO was detected by immunohistochemistry. Immune score were calculated, which are based on the combination of two lymphocyte populations (CD3/CD45RO, CD3/CD8 or CD8/CD45RO) both in the center (CT) and the invasive margin (IM) of tumors. T2W MRI images studies obtained in 34 patients before treatments, texture analysis by manually delineating a region of interest. The response rate, anus preservation rate were collected. The relationship among 53BP1 protein, immune score, texture analysis parameters and radiation sensitivity were explored by t-test. A new classifier was set to predict pathological response.

Results

The results indicated that the response rate in 53BP1 deletion group was significantly lower than that in 53BP1 high expression group (25.00% vs.84.44%, P < 0.005). "CD3+CD8" is the most reasonable immune score, the patients of 53BP1 deletion had lower immune score. The response rate in lower immune score group was lower than higher immune score group (54.54% vs.88.57%, P < 0.005). Texture analysis parameters were related with response rate. We set a new classifier to predict response in advanced rectal cancer, we randomly selected 10 patients as training group, others were selected as predict group, the accuracy is 83.33%.

Conclusions

A classifier of 53BP1, immune score and texture analysis of MRI can predict response in advanced rectal cancer.

Clinical trial identification

Legal entity responsible for the study

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology.

Funding

2015CFB659.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.